This three-part series focuses on the impact of geographic atrophy (GA) on patients and the specialists who treat them. In the third installment, Dr. Wykoff discusses disease progression and its impact on quality of life.
This educational activity is supported by Iveric Bio.
Not for credit.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Charles C. Wykoff, MD, PhD
Retina Consultants of Texas
Retina Consultants of America
Houston Methodist Hospital
Blanton Eye Institute
Houston, TX
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Charles C. Wykoff, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum Biotechnologies, Aerie Pharmaceuticals, AGTC, Alimera Sciences, Allergan, Allgenesis, Alnylam, Annexon, Apellis Pharmaceutcals, Arrowhead, Bausch + Lomb, Bayer, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Cholgene, Clearside Biomedical, Curacle, EyePoint Pharmaceuticals, Foresite, Frontera, Genentech, Gyroscope, IACTA, Iveric Bio, Janssen, Kato, Kiora, Kodiak Sciences, Kriya, Merck, Nanoscope, NGM Biopharmaceuticals, Notal Vision, Novartis, OccuRx, Ocular Therapeutix, OcuTerra, OliX, ONL, Opthea, Palatin, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, Regenxbio, Resonance, Roche, Stealth, Surrozen, Théa Pharma, TissueGen, Valo, Verana, and Vitranu. Grant/Research Support: 4DMT, Adverum Biotechnologies, Aerie Pharmaceuticals, AffaMed, Aldeyra, Alexion, Alimera Sciences, Alkahest, Allergan, Amgen, Annexon, Apellis Pharmaceuticals, AsclepiX Therapeutics, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Gemini, Genentech, Graybug Vision, Gyroscope, IONIS, iRENIX, Iveric Bio, Kodiak Sciences, LMRI, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocuphire Pharma, Opthea, Oxurion, Oyster Point Pharma, RecensMedical, Regeneron, Regenxbio, Roche, SamChunDang Pharm, Sandoz, Taiwan Liposome Company, UNITY, Verily, and Xbrane. Stock/Shareholder: ONL, PolyPhotonix, RecensMedical, TissueGen, Visgenx, and Vitranu.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Iveric Bio.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Janis T. Eells, Ph.D.
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
